Academic Editor: Giuseppe Ricci
Objective: Optimal management of ovarian cancer patients have been
investigated by several centers and have been discussed in a great number of
published articles. Aim of this article is the review of current data regarding
this lethal malignancy treatment. Moreover, we discuss the ongoing trials
regarding primary or interval cytoreductive surgery after neoadjuvant
chemotherapy. Mechanism: We reviewed the relevant literature regarding
ovarian cancer treatment via primary debulking surgery (PDS) as well as
neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS).
Findings in Brief: Our findings suggest that Neoadjuvant chemotherapy
(NACT) and interval debulking surgery (IDS) are alternative treatments for
advanced-stage ovarian cancer patients where optimal debulking surgery is
considered unfeasible, while some studies indicate that NACT/IDS offer similar
oncological outcomes with fewer postoperative complications. The prediction of
optimal debulking probability can be evaluated by CA-125 level